[]

Find Clinical Drug Pipeline Developments & Deals for Erlotinib Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MD Anderson Cancer Center

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 14, 2012

                          Lead Product(s) : Erlotinib Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute | Astellas Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Heather Wakelee

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Heather Wakelee

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 24, 2012

                          Lead Product(s) : Erlotinib Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Genentech | Novartis Pharmaceuticals Corporation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          NCIC Clinical Trials Group

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          NCIC Clinical Trials Group

                          Country arrow
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 15, 2010

                          Lead Product(s) : Erlotinib Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : GSK

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank